Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Janux Therapeutics Inc ( (JANX) ).
Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc., ceased to serve as Chief Strategy Officer and departed from the company effective September 18, 2025. His departure was classified as a termination without ‘Cause’ according to the company’s Change in Control and Severance Benefit Plan.
The most recent analyst rating on (JANX) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on Janux Therapeutics Inc stock, see the JANX Stock Forecast page.
Spark’s Take on JANX Stock
According to Spark, TipRanks’ AI Analyst, JANX is a Neutral.
Janux Therapeutics Inc’s stock score is primarily influenced by its strong revenue growth and solid balance sheet, but is offset by ongoing profitability challenges and negative cash flows from operations. Technical indicators suggest a neutral market sentiment, while valuation metrics highlight concerns due to negative earnings and lack of dividends.
To see Spark’s full report on JANX stock, click here.
More about Janux Therapeutics Inc
Average Trading Volume: 772,841
Technical Sentiment Signal: Sell
Current Market Cap: $1.41B
For an in-depth examination of JANX stock, go to TipRanks’ Overview page.